Double Whammy For Hi-Tech’s Zostrix: FDA Warning, NAD Review
This article was originally published in The Tan Sheet
Executive Summary
Soon after Hi-Tech Pharmacal received an FDA warning letter about violative diabetes claims for its Zostrix pain relief topicals, the National Advertising Division released a case report recommending several Zostrix claims be modified or discontinued due to inadequate clinical support.